Delivery Order SPE2DB22D2007-SPE2DB25FJ4AE
- Not listed
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $1,658.76 to AmerisourceBergen Drug Corp for the supply of Vyvanse capsules (30 mg) on August 20, 2025. This firm fixed-price delivery order, which is expected to be completed by August 21, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The award was competitively procured with no set-aside designation, leveraging...
- The Defense Logistics Agency awarded a delivery order valued at $2,675.40 to AmerisourceBergen Drug Corp for the supply of Vyvanse 40 mg capsules (100 count) on August 5, 2025, with an ultimate completion date of August 6, 2025. This competitively awarded, firm fixed price delivery order utilizes no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Vyvanse 40 mg capsules (100 count) with a ceiling value of $1,042.70. This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 4, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $2,437.80 to AmerisourceBergen Drug Corp for the supply of Vyvanse 30 mg capsules (100 count) on August 7, 2025, with completion scheduled for August 8, 2025. This non-competitive, firm fixed-price delivery order represents a single pharmaceutical transaction under the company's existing indefinite delivery contract with DLA Troop Support Medical. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Vyvanse 50 mg capsules (100-count units) with a contract value of $1,552.17. This competitively awarded, non-set-aside delivery order is structured as a firm fixed price contract with an ultimate completion date of July 23, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 10, 2025, for the supply of Vyvanse 40 mg capsules (100-count units) with a ceiling value of $2,584.08. This firm fixed-price delivery order, which is due for completion by June 11, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion vehicle running through December 2026. The award was...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Vyvanse 40 mg capsules (100 count) under a firm fixed price contract valued at $1,570.98. This is a non-set-aside competitive award, with an ultimate completion date of August 15, 2025. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Vyvanse 50 mg capsules (100-count units) with a contract value of $1,066.12 and an ultimate completion date of July 25, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and is performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award is issued under the company's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Vyvanse 20 mg capsules (100-count units) on August 25, 2025, with a ceiling value of $1,781.07 and an ultimate completion date of August 26, 2025. This contract was awarded competitively with no set-aside designation and utilizes firm fixed-price pricing. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Vyvanse 40 mg capsules (100 count units). This competitively awarded, firm fixed-price delivery order has a ceiling value of $2,517.96 and an ultimate completion date of August 26, 2025. The contract represents a child delivery order under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at...
- SPE2DB22D2007Indefinite Delivery Contract
- SPE2DB22D2007-SPE2DB25FJ4AEDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,057.40 to AmerisourceBergen Drug Corp for the supply of Vyvanse 40 mg capsules (100-count units) on August 18, 2025, with an ultimate completion date of August 19, 2025. The contract utilizes firm fixed pricing with no set-aside designation, indicating competitive award. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. AmerisourceBergen Drug Corp serves as a primary pharmaceutical distributor for federal military and veteran healthcare systems through this comprehensive global pharmaceutical support vehicle. The underlying IDC enables the company to supply a broad range of pharmaceutical products, generic and brand-name medications, vaccines, and medical supplies across multiple therapeutic domains to support military healthcare programs worldwide. This delivery order for Vyvanse, a controlled-release amphetamine medication used to treat attention deficit hyperactivity disorder and narcolepsy, represents a routine fulfillment of the company's broader contract obligations to the Defense Health Agency and other federal healthcare customers.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.1k | 8/18/25 |